Madison Asset Management LLC Cuts Stake in Medpace Holdings, Inc. $MEDP

Madison Asset Management LLC decreased its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 277,757 shares of the company’s stock after selling 14,872 shares during the period. Medpace makes up approximately 1.8% of Madison Asset Management LLC’s holdings, making the stock its 11th biggest position. Madison Asset Management LLC’s holdings in Medpace were worth $156,002,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. VIRGINIA RETIREMENT SYSTEMS ET Al raised its holdings in Medpace by 2.8% in the fourth quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 5,589 shares of the company’s stock worth $3,139,000 after buying an additional 150 shares during the last quarter. Valeo Financial Advisors LLC increased its holdings in shares of Medpace by 5.0% in the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. Swiss Life Asset Management Ltd raised its stake in shares of Medpace by 39.9% in the fourth quarter. Swiss Life Asset Management Ltd now owns 1,580 shares of the company’s stock worth $887,000 after purchasing an additional 451 shares during the last quarter. NewEdge Wealth LLC raised its stake in shares of Medpace by 9.3% in the fourth quarter. NewEdge Wealth LLC now owns 4,349 shares of the company’s stock worth $2,443,000 after purchasing an additional 371 shares during the last quarter. Finally, Crossmark Global Holdings Inc. lifted its holdings in shares of Medpace by 359.4% during the fourth quarter. Crossmark Global Holdings Inc. now owns 10,475 shares of the company’s stock valued at $5,883,000 after purchasing an additional 8,195 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Trading Up 0.6%

Shares of NASDAQ MEDP opened at $419.75 on Wednesday. Medpace Holdings, Inc. has a 12-month low of $284.48 and a 12-month high of $628.92. The firm has a market capitalization of $11.99 billion, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 2.12 and a beta of 1.19. The firm has a 50 day moving average of $466.29 and a 200 day moving average of $528.36.

Medpace (NASDAQ:MEDP) last released its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, topping the consensus estimate of $3.74 by $0.54. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period last year, the firm earned $3.67 earnings per share. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Sell-side analysts predict that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Key Medpace News

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest articles.
• Neutral Sentiment: Multiple law firms, including Pomerantz, Levi & Korsinsky, Bronstein Gewirtz & Grossman, The Schall Law Firm, The Gross Law Firm, Robbins Geller, Rosen, Faruqi & Faruqi, and BFA Law, issued class-action notices and deadline reminders for investors who purchased Medpace shares between April 22, 2025 and February 9, 2026.
• Negative Sentiment: The lawsuits allege Medpace and certain executives violated federal securities laws by making misleading disclosures, creating a significant legal and reputational risk that could weigh on the stock. Article Title
• Negative Sentiment: One article specifically cited a prior 16% drop tied to allegations that Medpace understated cancellation rates and overstated its book-to-bill ratio, reinforcing concern that the stock may remain volatile while the litigation develops. Article Title

Analysts Set New Price Targets

Several research firms recently commented on MEDP. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, April 6th. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Robert W. Baird decreased their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a report on Friday, April 24th. TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and lowered their price objective for the company from $462.00 to $419.00 in a research report on Wednesday, February 18th. Finally, Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. Four equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $467.08.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.